Categories: MedtechPlanning
Tioga Pharmaceuticals is planning to conduct a phase 2 trial of its selective kappa-opioid receptor agonist, asimadoline, for the treatment of associated with atopic pruritus.
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.04.2012 | Series B | $10M | - |
| 17.02.2010 | - | $18M | - |
Mentions in press and media 4
| Date | Title | Description |
| 13.04.2012 | Tioga Pharmaceuticals Closes $10M Series B Equity Financing | Tioga Pharmaceuticals, Inc., a San Diego, CA-based pharmaceutical company focused on developing novel treatments for gastrointestinal diseases, has closed a $10m Series B equity financing.
The round was led by new investor Thomas, McNerney ... |
| 12.04.2012 |
Tioga Pharmaceuticals Gets $10M
| San Diego-based Tioga Pharmaceuticals, a developer of biopharmaceuticals for treating irritable bowel syndrome, said today that it has raised $10M in a Series B funding round. The round was led by Thomas, McNerney & Partners, which also... |
| 17.02.2010 | Tioga Pharmaceuticals Raises $18M | San Diego-based Tioga Pharmaceuticals Inc...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
52 weekly issues
Subscriber-only digital content every business day, plus full access to SDBJ... |
| 17.02.2010 | Tioga Pharmaceuticals Raises $18M in Venture Capital Financing | Tioga Pharmaceuticals, Inc., a San Diego, CA-based pharmaceutical company focused on developing novel treatments for gastrointestinal diseases, closed an $18m equity financing.
Current investors Forward Ventures, New Leaf Venture Partners a... |
Reviews 0
